BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 951 filers reported holding BAXTER INTL INC in Q2 2014. The put-call ratio across all filers is 0.79 and the average weighting 0.4%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2019 | $234,000 | +5.9% | 2,856 | +5.1% | 0.02% | 0.0% |
Q1 2019 | $221,000 | +31.5% | 2,717 | +6.7% | 0.02% | -26.7% |
Q4 2018 | $168,000 | -12.5% | 2,547 | +2.3% | 0.03% | -75.8% |
Q3 2018 | $192,000 | -1.0% | 2,490 | -5.0% | 0.12% | -6.1% |
Q2 2018 | $194,000 | +14.8% | 2,622 | +0.8% | 0.13% | +14.8% |
Q1 2018 | $169,000 | -15.5% | 2,601 | -15.9% | 0.12% | -13.5% |
Q4 2017 | $200,000 | +3.1% | 3,091 | 0.0% | 0.13% | -0.7% |
Q3 2017 | $194,000 | 0.0% | 3,091 | -3.7% | 0.13% | +22.9% |
Q2 2017 | $194,000 | +16.2% | 3,211 | 0.0% | 0.11% | +19.8% |
Q1 2017 | $167,000 | +17.6% | 3,211 | 0.0% | 0.09% | -23.5% |
Q4 2016 | $142,000 | +1.4% | 3,211 | +9.1% | 0.12% | +0.8% |
Q3 2016 | $140,000 | +1455.6% | 2,943 | +1349.8% | 0.12% | +1211.1% |
Q2 2016 | $9,000 | +12.5% | 203 | 0.0% | 0.01% | +12.5% |
Q1 2016 | $8,000 | +60.0% | 203 | +45.0% | 0.01% | +60.0% |
Q4 2015 | $5,000 | +400.0% | 140 | +508.7% | 0.01% | +400.0% |
Q3 2015 | $1,000 | -66.7% | 23 | -47.7% | 0.00% | -50.0% |
Q2 2015 | $3,000 | 0.0% | 44 | 0.0% | 0.00% | 0.0% |
Q1 2015 | $3,000 | 0.0% | 44 | 0.0% | 0.00% | 0.0% |
Q4 2014 | $3,000 | +50.0% | 44 | +91.3% | 0.00% | 0.0% |
Q3 2014 | $2,000 | 0.0% | 23 | -23.3% | 0.00% | 0.0% |
Q2 2014 | $2,000 | 0.0% | 30 | 0.0% | 0.00% | 0.0% |
Q1 2014 | $2,000 | – | 30 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |